Novavax Begins Phase 2 Trial of its COVID-19 Vaccine

Novavax has enrolled the first patients in a phase 2 trial of its COVID-19 vaccine candidate NVX-CoV2373.

The trial will evaluate the vaccine’s safety and immunogenicity in 1,500 volunteers ages 18 to 84 in the U.S. and Australia. The trial will evaluate 5mcg and 25 mcg doses, each with 50 mcg of Novavax’s Matrix-M adjuvant.

The phase 1 portion of the trial in Australia found that the vaccine was well-tolerated and generated better antibody responses than those seen in recovered COVID-19 patients.